Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Back Pain Lower Back Chronic, Chronic Pain
Interventions
Buprenorphine Buccal Film [Belbuca], Urine Drug Screening, actigraph, PROMIS 29, sit to stand test, numerical rating scale pain score, patient global impression of function, PROMIS - sleep
Drug · Other · Device + 1 more
Lead sponsor
Carolinas Pain Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Terminated Phase 1Phase 2 Interventional Results available

Topical Irrigation Therapy for CRS

NCT02630472
Conditions
Rhinitis, Sinusitis
Interventions
Quinine Sulfate, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Asthma
Interventions
BreatheSmart System, Standard of Care
Device · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Safety, and Tolerability
Interventions
DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg
Combination Product · Drug
Lead sponsor
Aspeya Switzerland SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Non-syndromic Retinitis Pigmentosa
Interventions
Gene therapy: GS030-DP AND Medical device: GS030-MD
Combination Product
Lead sponsor
GenSight Biologics
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Results available

Asthma Controller Adherence After Hospitalization

NCT02615743
Conditions
Asthma
Interventions
Daily Text message reminder, Inhaled steroid canister monitor
Behavioral · Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 11 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hematologic Malignancies
Interventions
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
Device · Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Conditions
Overweight, Obese, Type 1 Diabetes Mellitus
Interventions
CT-868, CT-868 Pen Injector, CT-868 Pen Injector, Placebo
Drug · Device
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Concord, California • Escondido, California • Aurora, Colorado + 17 more
Conditions
Stroke
Interventions
Sedation, General Anesthesia (GA), Intra-arterial Thrombectomy
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 90 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Louisville, Kentucky + 6 more
Conditions
Osteoporosis
Interventions
abaloparatide-sMTS (Patheon), abaloparatide-sMTS (Kindeva)
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Cigarette Smoking, Drug Use
Interventions
Standard Treatment, BAD-AS, Transdermal Nicotine Patch
Behavioral · Drug
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Active, not recruiting Not applicable Interventional

Brain Oxygen Optimization in Severe TBI, Phase 3

NCT03754114
Conditions
Brain Injuries, Traumatic
Interventions
ICP + PbtO2 guided management strategy, ICP guided management strategy
Other
Lead sponsor
University of Michigan
Other
Eligibility
14 Years and older
Enrollment
1,094 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
48
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 38 more
Completed Phase 4 Interventional Results available

The END Perioperative Smoking Pilot Study

NCT02482233
Conditions
Smoking, Nicotine Addiction, Surgery
Interventions
ENDD (NJOY), NRT (NicoDerm CQ), telephone counseling, brief advice, brochure
Behavioral · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Feasibility of Polychromatic Light Emitting Diode System to Reduce Pain

NCT03246282
Conditions
Pain
Interventions
UVL1000 Treatment Station, Normal Saline 0.9% Infusion Solution Bag, Peripheral Catheterization
Device · Drug
Lead sponsor
John W. Reeves, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Shreveport, Louisiana
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Nicotine Delivery Systems: Research & Treatment

NCT00108342
Conditions
Smoking
Interventions
Nicotine gum - 2 mg and 4 mg, Nicotine lozenges - 2 mg and 4 mg, Nicotine inhaler (4 mg yield) - low and high "dosage" by frequency of puffing, Computer learning
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Los Angeles, California
Conditions
Acute Kidney Injury
Interventions
SBI-101, Sham
Biological · Device
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Allentown, Pennsylvania
Conditions
Sickle Cell Disease
Interventions
Hematopoietic Stem Cell Transplantation, CliniMACS, See intervention description
Procedure · Device · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 16 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
THC, Cannabis, Cannabis Use, Cannabis Smoking, Tobacco Use, Vaping
Interventions
Cannabis, Nicotine, Pax Loose Leaf Vaporizer, Placebo Marijuana
Drug · Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Stage D Heart Failure
Interventions
Sacubitril-Valsartan, Usual care (standard-of-care) arm
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
Fibroscan of Liver, Low-dose non-contrast CT
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Vasculogenic Erectile Dysfunction
Interventions
Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.
Device
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 4 Interventional Results available

Geriatric Ketamine for Pain Management Study

NCT02673372
Conditions
Pain
Interventions
Morphine, Ketamine
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
65 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
COVID-19
Interventions
REGN10933+REGN10987 combination therapy, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
96
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 70 more